8-K Announcements
6Material company update
May 20, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
Mar 25, 2026·SEC
ProMIS Neurosciences, Inc.(PMN)Earnings, Financials & Key Ratios
PMN•NASDAQ
$13.71
Price updated Jul 6, 2026
AboutProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Show more
- Revenue$0
- EBITDA-$40M-1490.9%
- Net Income-$40M-1529.3%
- EPS (Diluted)-22.61-922.2%
- ROE-521.61%-1999.7%
PMN Price & Volume
ProMIS Neurosciences, Inc. (PMN) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Capital Reserves
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- ProMIS Neurosciences remains a high-risk, pre-revenue biotechnology entity heavily reliant on external financing to sustain its PMN310 clinical program.
- While the company focuses exclusively on R&D, the lack of commercial revenue and persistent operating losses create a precarious financial outlook.
- Investors should monitor the company's ability to secure non-dilutive funding, as the current trajectory suggests significant ongoing capital requirements that may continue to erode shareholder equity.
Verdict Logic
the company's cash position of $6.1 million against quarterly operating losses exceeding $8 million suggests an imminent liquidity crisis that likely necessitates highly dilutive equity financing.
PMN Growth Metrics
ProMIS Neurosciences, Inc. (PMN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-4248.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2270.85%
Return on Capital
10 Years-579.25%
5 Years-347.23%
3 Years-480.58%
Last Year-519.51%
PMN Recent Earnings
ProMIS Neurosciences, Inc. (PMN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$1.26-18.9%
$1.06
Rev
—
—
Q2 2026
May 11, 2026Metric
Actual
Est
EPS
$1.26-18.9%
$1.06
Rev
—
—
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$4.11+11.8%
$4.66
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$6.00-60.0%
$3.75
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $1.26vs $1.06-18.9% | — |
| Q2 2026 | May 11, 2026 | $1.26vs $1.06-18.9% | — |
| Q2 2026 | Mar 25, 2026 | $4.11vs $4.66+11.8% | — |
| Q4 2025 | Nov 12, 2025 | $6.00vs $3.75-60.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for ProMIS Neurosciences, Inc. (PMN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.71 | $89.5M | -0.61 | — | — | -521.61% | — | |
| $9.50 | $497.36M | -2.10 | -92.84% | -260.92% | -49.88% | — | |
| $8.45 | $545.2M | -6.60 | -0.3% | -247.54% | -44.39% | — | |
| $25.77 | $4.41B | 11.25 | 11.87% | 34.3% | 35.65% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $3.95 | $68.19M | -2.94 | — | -1070.26% | — | — |
Compare PMN vs Peers
ProMIS Neurosciences, Inc. (PMN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PMN SEC Filings & Documents
ProMIS Neurosciences, Inc. (PMN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PMN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PMN Frequently Asked Questions
ProMIS Neurosciences, Inc. (PMN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is PMN profitable?
ProMIS Neurosciences, Inc. (PMN) reported a net loss of $40.6M for fiscal year 2025.
Dividend & Returns
What is PMN's return on equity?
ProMIS Neurosciences, Inc. (PMN) has a return on equity (ROE) of -521.6%. Negative ROE indicates the company is unprofitable.
What is ProMIS Neurosciences, Inc.'s free cash flow?
ProMIS Neurosciences, Inc. (PMN) had negative free cash flow of $35.5M in fiscal year 2025, likely due to heavy capital investments.